Thyrocare Reports Robust Q1FY27 Results – Revenue Up 24%, PAT Up 34%
The company delivered a robust performance in Q1FY27 with consolidated revenue of ₹240.02 crore, registering a strong 24% year-on-year growth, led by continued momentum in the Pathology segment which grew 26% YoY. EBITDA rose by 34% YoY to ₹77.27 crore. Profit After Tax surged 34% YoY to ₹51.33 crore, underscoring the company’s focus on profitable growth.
India’s largest diagnostic test volume processor further strengthened its volume leadership position during the quarter, processing 55.2 million tests up 28% year-on-year. The Pathology business maintained strong traction with franchise revenue up 27% and partnership revenue up 26% year-on-year.
Thyrocare's unwavering commitment to quality delivered Six Sigma excellence by reducing complaints to 3.1 per million (down 24% YoY) with ATAT at 3.37 hours from sample receipt, positioning the company as India's first diagnostic chain to attain this benchmark.
Thyrocare expanded into Specialty Diagnostics, marking the next phase of its growth journey and the next frontier of diagnostics. The Company commenced this journey with Allergy and Genomics and progressively expanded its specialty test portfolio, with a focus on building clinical trust through scientific rigor, uncompromising quality, and industry-leading turnaround times
Consolidated Financial Performance for Q1FY27
Senior management remarks:
“Thyrocare reported a strong performance this quarter, driven by continued focus on operational efficiency, network expansion, and value-driven diagnostics. During the period, we also strengthened our specialty portfolio with the addition of allergy testing and entry into genomics through the launch of NIPT, with a phased expansion of the test menu underway. Thyrocare continues to expand its reach in underserved regions and scale its franchise and partner network, while remaining committed to delivering high-quality, affordable healthcare services across India”
– Rahul Guha, MD & CEO, Thyrocare Technologies Ltd.
